Next Safety, Inc. Announces Bid Date for the Sale of the Company's Platform for the Pulmonary Delivery of Albuterol and the Components of Advair(TM)

Published: Dec 23, 2008

JEFFERSON, N.C., Dec. 22 /PRNewswire/ -- Next Safety has developed a proprietary platform that delivers nicotine and a number of other drugs including albuterol and the components of Advair(TM), fluticasone propionate and salmeterol xinofoate, in air timed to the user's inhalation. Certain US patents for the chemical components of Advair(TM) expired September 2008.

Next Safety's platform has numerous advantages over current methods used for delivering these significant asthma medications. The benefits include the use of air instead of refrigerant-based propellants and the delivery of medication timed to the user's inhalation, unlike dry powder inhalation devices.


NSI has decided to sell intellectual property and other related assets for the pulmonary delivery of certain asthma medications, utilizing its proprietary platform, in a competitive bidding process that includes a number of leading, global pharmaceutical companies.

According to Eric Hunter, CEO of Next Safety, "We are selling the assets related to the pulmonary delivery of albuterol, fluticasone and salmeterol in a bid process that ends February 12, 2009."

This release was issued through eReleases(TM). For more information, visit

CONTACT: George Colvard, COO,, or Philip
Weaver, President,, both of Next Safety

Web site:

Back to news